NEW YORK, March 19 – Toronto-based proteomics company Syn X Pharma said Monday it would build the infrastructure to conduct in-house clinical trials.

The company, which recently hired a proteomics executive from Ciphergen and a business development expert from Eli Lilly, said the move signaled its efforts to begin bringing its products to market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.